s 16020-2 has been researched along with Colonic Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alvord, WG; Gray-Goodrich, M; Jeffers, M; Kohlhagen, G; Koo, HM; McWilliams, MJ; Monks, A; Paull, KD; Pommier, Y; Vaigro-Wolff, A; Vande Woude, GF | 1 |
Atassi, G; Burbridge, MF; Guilbaud, N; Jan, M; Kraus-Berthier, L; Pierré, A; Rouillon, MH; Saint-Dizier, D | 1 |
2 other study(ies) available for s 16020-2 and Colonic Neoplasms
Article | Year |
---|---|
The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Carbazoles; Colonic Neoplasms; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, ras; Humans; Mutation; Phenotype; Pyridines; Topoisomerase II Inhibitors; Transfection; Tumor Cells, Cultured | 1999 |
Experimental antitumour activity of S 16020-2 in a panel of human tumours.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Ellipticines; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |